HQNO
(Synonyms: 2-庚基-4-羟基喹啉-N-氧化物,KF8940,N-oxo-2-heptyl-4-Hydroxyquinoline,Pyo II) 目录号 : GC15529
A respiratory chain inhibitor
Cas No.:341-88-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HQNO is a NADH oxidase inhibitor.
The NADPH oxidase, a membrane-bound enzyme complex facing the extracellular space, can be found in the plasma membrane and in the membranes of phagosomes used by neutrophil white blood cells to engulf microorganisms. Isoforms are designated NOX1, NOX2, NOX3, as well as NOX4.
In vitro: Previous study found that HQNO could inhibit the Na+-dependent NADH oxidase but had very limited effect on the NA+-independent activity of mutant membranes. Moreover, the NADH:quinone oxidoreductase was observed to be the Na+-dependent HQNO-sensitive site of the NADH oxidase. In addition, HQNO was found to be able to cause a strong inhibition of the Na+ pump with limited effect on the overall H+ extrusion by respiration in the wild type cells. The inhibition of the Na+ pump by HQNO could be overcome by oxidized but not reduced TMPD. The electron flow NADH to oxygen appeared to bypass the HQNO-sensitive site and energize the Na+ pump in the presence of oxidised TMPD [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Tokuda, H. , and Unemoto, T. Na+ is translocated at NADH:quinone oxidoreductase segment in the respiratory chain of Vibrio alginolyticus. The Journal of Biological Chemisty 259(12), 7785-7790 (1984).
| Cas No. | 341-88-8 | SDF | |
| 别名 | 2-庚基-4-羟基喹啉-N-氧化物,KF8940,N-oxo-2-heptyl-4-Hydroxyquinoline,Pyo II | ||
| 化学名 | 2-heptyl-1-hydroxyquinolin-4(1H)-one | ||
| Canonical SMILES | CCCCCCCC1=CC(C2=CC=CC=C2N1O)=O | ||
| 分子式 | C16H21NO2 | 分子量 | 259.34 |
| 溶解度 | ≥ 25.9mg/mL in ETOH with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8559 mL | 19.2797 mL | 38.5594 mL |
| 5 mM | 0.7712 mL | 3.8559 mL | 7.7119 mL |
| 10 mM | 0.3856 mL | 1.928 mL | 3.8559 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet